IPA ImmunoPrecise Antibodies
- 1.370
- +0.050+3.80%
ImmunoPrecise Antibodies News
ImmunoPrecise Antibodies | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ImmunoPrecise Antibodies | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ImmunoPrecise Antibodies | 6-K: Report of foreign private issuer (related to financial reporting)
ImmunoPrecise Antibodies | 6-K: Report of foreign private issuer (related to financial reporting)
ImmunoPrecise Antibodies | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ImmunoPrecise Antibodies | SC 13G: Statement of acquisition of beneficial ownership by individuals-INGALLS & SNYDER LLC(5.01%)
ImmunoPrecise Antibodies | 6-K: Report of foreign private issuer (related to financial reporting)
ImmunoPrecise Antibodies | 424B5: Prospectus
ImmunoPrecise Antibodies | 6-K/A: Report of foreign private issuer (related to financial reporting)
ImmunoPrecise Antibodies | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Charmquark TWEE(6.28%),Charmquark EEN(6.28%)
ImmunoPrecise Antibodies | SC 13G: Statement of acquisition of beneficial ownership by individuals-Charmquark TWEE(6.40%),Charmquark EEN(6.40%)
ImmunoPrecise Antibodies | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ImmunoPrecise Antibodies | 6-K: Report of foreign private issuer (related to financial reporting)
ImmunoPrecise Antibodies | 6-K: Report of foreign private issuer (related to financial reporting)
ImmunoPrecise Antibodies | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ImmunoPrecise Antibodies | 424B5: Prospectus
ImmunoPrecise Antibodies | 6-K: Report of foreign private issuer (related to financial reporting)
ImmunoPrecise Antibodies | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ImmunoPrecise Antibodies | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
ImmunoPrecise Antibodies | 424B5: Prospectus
Analysis
Price Target
No Data
